Dare Bioscience, Inc.

Daré Bioscience develops pharmaceutical therapies focused on women's health, with a portfolio spanning contraception, sexual health, fertility support, menopause management, and infectious disease treatment. The company's marketed product is XACIATO, a lincosamide antibacterial gel for bacterial vaginosis. Its clinical-stage pipeline includes multiple contraceptive candidates such as Ovaprene (hormone-free intravaginal monthly option), DARE-LARC1 (levonorgestrel implant), and DARE-204/DARE-214 (injectable formulations providing 6- and 12-month protection). Additional development programs address female sexual arousal disorder, dyspareunia, dysmenorrhea, menopausal vasomotor symptoms, HPV-related infection, preterm birth prevention, and vaginal microbiome health.

The company operates as a clinical-stage biotechnology firm with 21 full-time employees and is headquartered in San Diego, California. Daré Bioscience was incorporated in Delaware and founded in 2015. The organization is publicly listed on Nasdaq, though revenue generation remains limited given the early-stage nature of most pipeline assets and the single approved product on market.